Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure

NCT ID: NCT02430805

Last Updated: 2015-04-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2015-02-28

Brief Summary

This project aims at investigating the genetic, genomic and proteomic basis of hypertension and susceptibility to hypertension-related end organ damage (renal damage and heart failure). It will include cross sectional as well as follow-up studies with a large number of subjects and variety of phenotypes, to explore the pathophysiology of hypertension and hypertension-related disease.

Detailed Description

In all index patients and recruited family members, recorded data will include the following :

• Past medical history, drug history and family history
• Physical examination
• Height, weight, waist and hip circumference
• Cardiac examination
• Vascular examination
• Blood pressure
• Plasma and urine samples
• Body composition (DEXA)
• Tissue Doppler imaging

Conditions

Hypertension

Keywords

hypertension; microinflammation and oxidative stress; renal disease; heart failure; genetics markers; genomics markers; proteomics markers

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Study Groups

NOE

multicentric family-based cohort. prospective and transversal study

Group Type: OTHER

dna extraction and genotyping

Intervention Type: OTHER

blood and urine sample

Interventions

dna extraction and genotyping

blood and urine sample

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• index patient :

• Caucasian patients of either sex who were diagnosed to have essential hypertension (as defined below) before the age of 50 y.
• The index patient should not be older than 60 years at the time of enrolment.
• Definition of hypertension for the index patient:

• If untreated: Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 95 mmHg.
• If already on treatment: Treatment with more of 2 different antihypertensive drugs at the time of enrolment.
• At least three first degree relatives of whom at least one should be affected and at least one be from a different generation (parents or offspring aged 18 years or above) must be willing to participate in the family study. For definition of hypertension in relatives of the index patient see below.
• Written informed consent
• family

• at least three other first degree relatives must be willing to participate in the family study:
• at least one first-degree relative must be affected with diagnosis of hypertension made before age of 50 years AND
• at least one first degree relative must be from a different generation (offspring or parents).

Exclusion Criteria

• index patient :

• Any known form of secondary hypertension, including sleep apnoea syndrome
• Any known previous clinical complications of hypertension (angina, MI, stroke, TIA, peripheral artery disease) at any time
• Any known renal disease, including GFR < 60 mL/min as estimated by the abbreviated MDRD formula, or kidney stones
• Kidney or other organ transplantation
• Type 1 diabetes mellitus
• Heart failure stage D (AHA/ACC criteria)
• Any malignant concomitant diseases or history of malignant diseases within the last five years, with exception of treated squamous skin cancer or basalioma
• Clinical or laboratory signs of acute infection, especially urinary tract infection
• Systemic inflammatory diseases, such as autoimmune diseases, connective tissue diseases or collagenoses.
• Steroids or any other immunosuppressive drug
• Severe known liver disease (ALT or gamma-GT above three-fold of upper normal limit)
• Current alcohol consume of more than 21 drinks/week (1 drink = a bottle (0,33 l) beer, a glass (0,2 l) of wine, or 4 cl = 40 ml of spirit (40%)) or drug abuse such as cocaine
• family

• any organ transplantation
• any malignant concomitant disease
• acute infection
• systemic inflammatory disease
• severe liver disease
• current alcohol or drug abuse

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Network of Excellence 6 PCRD

OTHER

Sponsor Role: collaborator

Central Hospital, Nancy, France

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

faiez ZANNAD, Pr

Role: PRINCIPAL_INVESTIGATOR

Central Hospital, Nancy, France

Locations

Centre D'Investigation Clinique de Strasbourg

Strasbourg, Alsace, France

Hopital Brabois adulte

Nancy, Lorraine, France

Countries

France

References

Mandry D, Girerd N, Lamiral Z, Huttin O, Filippetti L, Micard E, Beaumont M, Ncho Mottoh MB, Pace N, Zannad F, Rossignol P, Marie PY. Relationship Between Left Ventricular Ejection Fraction Variation and Systemic Vascular Resistance: A Prospective Cardiovascular Magnetic Resonance Study. Front Cardiovasc Med. 2021 Dec 24;8:803567. doi: 10.3389/fcvm.2021.803567. eCollection 2021.

Reference Type: DERIVED

PMID: 35004914 (View on PubMed)

Other Identifiers

Cpp : 07.11.11

Identifier Type: -

Identifier Source: secondary_id

Dgs: 2007-0537

Identifier Type: -

Identifier Source: secondary_id

HYPERCARE(english v. 1.0)JRPB3

Identifier Type: -

Identifier Source: org_study_id